FR2959994B1 - Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii - Google Patents

Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii

Info

Publication number
FR2959994B1
FR2959994B1 FR1053712A FR1053712A FR2959994B1 FR 2959994 B1 FR2959994 B1 FR 2959994B1 FR 1053712 A FR1053712 A FR 1053712A FR 1053712 A FR1053712 A FR 1053712A FR 2959994 B1 FR2959994 B1 FR 2959994B1
Authority
FR
France
Prior art keywords
novel
directed against
mutus
humanized antibodies
hormone receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1053712A
Other languages
English (en)
French (fr)
Other versions
FR2959994A1 (fr
Inventor
Christian Behrens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Montpellier
LFB SA
Institut Regional du Cancer de Montpellier
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre National de Lutte Contre Le Cancer
LFB Biotechnologies SAS
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1053712A priority Critical patent/FR2959994B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre National de Lutte Contre Le Cancer, LFB Biotechnologies SAS, Universite de Montpellier filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to EP11718450.7A priority patent/EP2569333B1/fr
Priority to ES11718450.7T priority patent/ES2661080T3/es
Priority to JP2013509591A priority patent/JP6043998B2/ja
Priority to PCT/FR2011/050745 priority patent/WO2011141653A1/fr
Priority to DK11718450.7T priority patent/DK2569333T3/en
Priority to CA2798336A priority patent/CA2798336C/fr
Priority to CN201180032211.8A priority patent/CN103119059B/zh
Priority to BR112012028859-8A priority patent/BR112012028859B1/pt
Priority to US13/697,575 priority patent/US9012607B2/en
Priority to ARP110101115A priority patent/AR081159A1/es
Publication of FR2959994A1 publication Critical patent/FR2959994A1/fr
Application granted granted Critical
Publication of FR2959994B1 publication Critical patent/FR2959994B1/fr
Priority to US14/658,785 priority patent/US9637544B2/en
Priority to JP2016146495A priority patent/JP6435295B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
FR1053712A 2010-05-12 2010-05-12 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii Active FR2959994B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR1053712A FR2959994B1 (fr) 2010-05-12 2010-05-12 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
ARP110101115A AR081159A1 (es) 2010-05-12 2011-04-01 Anticuerpos humanizados 12g4 mutados y sus fragmentos dirigidos contra el receptor humano de la hormona anti-mulleriana de tipo ii
JP2013509591A JP6043998B2 (ja) 2010-05-12 2011-04-01 ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント
PCT/FR2011/050745 WO2011141653A1 (fr) 2010-05-12 2011-04-01 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
DK11718450.7T DK2569333T3 (en) 2010-05-12 2011-04-01 NEW MUTERATED HUMANIZED 12G4 ANTIBODIES AND FRAGMENTS THEREOF AGAINST THE HUMAN TYPE II RECEPTOR FOR ANTI-MULLER HORMON
CA2798336A CA2798336C (fr) 2010-05-12 2011-04-01 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
EP11718450.7A EP2569333B1 (fr) 2010-05-12 2011-04-01 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
BR112012028859-8A BR112012028859B1 (pt) 2010-05-12 2011-04-01 Novos anticorpos 12g4 humanizados mutados e fragmentos destes direcionados contra o receptor tipo ii do hormônio anti-mülleriano humano
US13/697,575 US9012607B2 (en) 2010-05-12 2011-04-01 Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
ES11718450.7T ES2661080T3 (es) 2010-05-12 2011-04-01 Nuevos anticuerpos humanizados 12G4 mutados y sus fragmentos dirigidos contra el receptor humano de la hormona anti-mulleriana de tipo II
CN201180032211.8A CN103119059B (zh) 2010-05-12 2011-04-01 针对人抗苗勒管激素ii型受体的新的突变型人源化12g4抗体及其片段
US14/658,785 US9637544B2 (en) 2010-05-12 2015-03-16 Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
JP2016146495A JP6435295B2 (ja) 2010-05-12 2016-07-26 ヒト抗−ミューラー管ホルモンｉｉ型レセプターを指向する新規な変異ヒト化１２ｇ４抗体及びそのフラグメント

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1053712A FR2959994B1 (fr) 2010-05-12 2010-05-12 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii

Publications (2)

Publication Number Publication Date
FR2959994A1 FR2959994A1 (fr) 2011-11-18
FR2959994B1 true FR2959994B1 (fr) 2012-08-24

Family

ID=43413855

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1053712A Active FR2959994B1 (fr) 2010-05-12 2010-05-12 Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii

Country Status (11)

Country Link
US (2) US9012607B2 (https=)
EP (1) EP2569333B1 (https=)
JP (2) JP6043998B2 (https=)
CN (1) CN103119059B (https=)
AR (1) AR081159A1 (https=)
BR (1) BR112012028859B1 (https=)
CA (1) CA2798336C (https=)
DK (1) DK2569333T3 (https=)
ES (1) ES2661080T3 (https=)
FR (1) FR2959994B1 (https=)
WO (1) WO2011141653A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016576A1 (en) 2011-07-26 2013-01-31 United Parcel Service Of American, Inc. Systems and methods for managing fault codes
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
US10509035B2 (en) * 2015-08-07 2019-12-17 Gamamabs Pharma Sa Antibodies, antibody drug conjugates and methods of use
WO2017079303A1 (en) * 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
FR3060394B1 (fr) * 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combinaison d'anticorps anti-cd303 et anti-amhrii
KR20200014276A (ko) 2017-04-14 2020-02-10 가마맵스 파마 암을 예방 또는 치료하기 위한 amhrii-결합 화합물
US20230227566A1 (en) * 2017-04-14 2023-07-20 Gamamabs Pharma Amhrii-binding compounds for preventing or treating lung cancers
CN111108123A (zh) * 2017-05-29 2020-05-05 加马玛布斯制药公司 癌症相关的免疫抑制抑制剂
EP3789401A1 (en) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
WO2021155295A1 (en) * 2020-01-31 2021-08-05 The Cleveland Clinic Foundation Anti-müllerian hormone receptor 2 antibodies and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005005615A2 (en) * 2003-07-08 2005-01-20 Fox Chase Cancer Center Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer
CA2631327C (en) * 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
WO2007117657A2 (en) * 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
WO2007134037A2 (en) * 2006-05-15 2007-11-22 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
EP1918304A1 (en) * 2006-11-02 2008-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)

Also Published As

Publication number Publication date
CN103119059B (zh) 2016-06-29
FR2959994A1 (fr) 2011-11-18
JP2017029139A (ja) 2017-02-09
JP2013534408A (ja) 2013-09-05
BR112012028859A8 (pt) 2017-12-05
ES2661080T3 (es) 2018-03-27
BR112012028859B1 (pt) 2022-02-22
CA2798336A1 (fr) 2011-11-17
US20150232563A1 (en) 2015-08-20
CN103119059A (zh) 2013-05-22
EP2569333A1 (fr) 2013-03-20
CA2798336C (fr) 2018-08-21
BR112012028859A2 (https=) 2017-08-15
JP6043998B2 (ja) 2016-12-14
WO2011141653A1 (fr) 2011-11-17
JP6435295B2 (ja) 2018-12-05
AR081159A1 (es) 2012-07-04
DK2569333T3 (en) 2018-03-26
EP2569333B1 (fr) 2017-12-13
US20130136743A1 (en) 2013-05-30
US9637544B2 (en) 2017-05-02
US9012607B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
FR2959994B1 (fr) Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
FR25C1055I1 (fr) Anticorps anti-peptide beta-amyloide n3pglu et leurs utilisations
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
PH12015500977A1 (en) Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
PH12013501942A1 (en) Antibody-drug conjugates
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
EP2582722A4 (en) ANTIBODIES AGAINST GD2
EP2501724A4 (en) MONOCLONAL ANTIBODIES AND DIAGNOSTIC USES THEREOF
PH12012501793B1 (en) Monoclonal antibodies against c-met
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
EP2604626A4 (en) FRAGMENT OF A HUMANIZED ANTI-EGFR ANTIBODY, VARIABLE FRAGMENT OF SUBSTITUTED LYSINE AND USE THEREOF
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
PH12013501971B1 (en) Anti-sclerostin antibody crystals and formulations thereof
EP3735271A4 (en) ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
EP2582729A4 (en) ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
EP2921503A4 (en) HUMANIZED ANTIBODIES AGAINST HUMAN EPIDEMIC GROWTH FACTOR RECEPTOR AND CODING GENE AND APPLICATION THEREOF
ZA201304459B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EP2399934A4 (en) NEW MONOCLONAL ANTIBODY AND USE THEREOF
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EP3837286A4 (en) ANTIBODIES TO HUMAN ZNT8

Legal Events

Date Code Title Description
CL Concession to grant licences

Name of requester: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130619

Name of requester: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130624

Name of requester: LFB BIOTECHNOLOGIES, FR

Effective date: 20130619

Name of requester: LFB BIOTECHNOLOGIES, FR

Effective date: 20130624

TQ Partial transmission of property

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130820

Owner name: UNIVERSITE MONTPELLIER I, FR

Effective date: 20130820

Owner name: CENTRE NATIONAL DE LUTTE CONTRE LE CANCER, FR

Effective date: 20130820

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Effective date: 20130820

CL Concession to grant licences

Name of requester: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20140617

Name of requester: LFB BIOTECHNOLOGIES, FR

Effective date: 20140617

Name of requester: GAMAMABS PHARMA, FR

Effective date: 20140617

PLFP Fee payment

Year of fee payment: 7

RM Correction of a material error

Effective date: 20161205

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

TQ Partial transmission of property

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Effective date: 20180725

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20180725

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20180725

Owner name: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER, FR

Effective date: 20180725

CD Change of name or company name

Owner name: ICM INSTITUT REGIONAL DU CANCER DE MONTPELLIER, FR

Effective date: 20181004

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Effective date: 20181004

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20181004

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20181004

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

CA Change of address

Effective date: 20221108

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16